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A B S T R A C T
Recent evidence has continued to support the applicability of progesterone in preventing preterm birth, hence
the development of an appropriate vaginal delivery system for this drug would be of considerable interest. Here,
we describe the development of progesterone-loaded bioadhesive nanoﬁbers using pressurized gyration for
potential incorporation into a vaginal insert, with a particular view to addressing the challenges of incorporating
a poorly water-soluble drug into a hydrophilic nanoﬁber carrier. Polyethylene oxide and carboxymethyl cellu-
lose were chosen as polymers to develop the carrier systems, based on previous evidence of their yielding
mucoadhesive nanoﬁbers using the pressurized gyration technique. The fabrication parameters such as solvent
system, initial drug loading and polymer composition were varied to facilitate optimisation of ﬁber structure and
eﬃciency of drug incorporation. Such studies resulted in the formation of nanoﬁbers with satisfactory surface
appearance, diameters in the region of 400 nm and loading of up to 25% progesterone. Thermal and spectro-
scopic analyses indicated that the drug was incorporated in a nanocrystalline state. Release from the drug-loaded
ﬁbers indicated comparable rates of progesterone dissolution to that of Cyclogest, a commercially available
progesterone pessary, allowing release over a period of hours. Overall, the study has shown that pressurized
gyration may produce bioadhesive progesterone-loaded nanoﬁbers which have satisfactory loading of a poorly
water-soluble drug as well as having suitable structural and release properties. The technique is also capable of
producing ﬁbers at a yield commensurate with practical applicability, hence we believe that the approach shows
considerable promise for the development of progesterone dosage forms for vaginal application.
1. Introduction
Preterm delivery, as deﬁned by the WHO, refers to babies born alive
before 37 weeks of pregnancy are completed; the associated sub-cate-
gories, according to gestational age, are extremely preterm
(< 28weeks), very preterm (28 – 32weeks) and moderate to late
preterm (32 – 37weeks) (WHO, 2004, 2015). Common predetermining
factors for this condition include multiple pregnancies, infections and
chronic conditions such as hypertension and diabetes, although for a
signiﬁcant number of cases the cause is not known (Vogel et al., 2016).
Preterm births occur among 5–18% of all live births around the world,
with about 60% of all incidence recorded in low income countries,
particularly in Asia and Africa, and is a major contributing factor to
neonatal mortality and morbidity as well as long-term adverse out-
comes on health and quality of life. For example, a meta-analysis con-
ducted for the Global Burden of Disease Study 2010 data attributed 77
million (3.1%) disability-adjusted life years to preterm birth, an esti-
mate comparable to burden of HIV or malaria (3.3% each) (Murray
et al., 2012; Lee et al., 2013; Romero et al., 2014). This condition is
therefore a global health challenge and requires the development of
eﬀective interventions to mitigate its impact, especially in low income
countries where the most damaging eﬀects are seen (Beck et al., 2010).
Progesterone, an endogenous steroidal hormone crucial for human
reproduction can be administered orally as a solid dosage form, par-
entally (subcutaneous and intramuscular as oil-based injections) or
topically (as a pessary, cream or vaginal gel) for a variety of indications
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(Brayﬁeld, 2017). In the 1980s and 90s, progesterone was widely used
in the prevention of preterm labour until safety concerns halted its use
(Fuchs et al., 2014). Promising results from recent randomised con-
trolled clinical trials have however, revived interest in the use of pro-
gesterone for the prevention of preterm labour. Indeed, a Cochrane
Database of Systematic Review study concluded that progesterone sig-
niﬁcantly reduced the incidence of preterm labour, especially for
women with history of spontaneous preterm birth (Dodd et al., 2008).
Given the necessity of ﬁnding new and eﬀective means of pre-
venting preterm labour, there is a clear need to develop a wider range
of progesterone based formulations, particularly in order to overcome
some of the limitations of the currently available products. In terms of
vaginal delivery, existing approaches have been hindered by poor re-
tention and intermittent leakages, often leading to reduced residence
time and ultimately poor bioavailability (Neves et al., 2014). A number
of approaches have been used to deliver drugs topically to the vagina,
including inserts such as vaginal rings which may overcome the issue of
retention while allowing controlled release. Bioadhesive monolith sys-
tems may also be used whereby the drug is incorporated into an insert
which allows prolonged contact with the vaginal mucosa (Neves et al.,
2014). Medicated tampon devices have also been explored as micro-
bicide delivery systems for prevention of HIV transmission (Ball et al.,
2012) The approach described in this study is to develop a bioadhesive
nanoﬁbrous system which could be processed into suitable dosage
forms (particularly, we suggest, as a medicated tampon) for vaginal
drug delivery. We believe that such an approach holds several potential
beneﬁts including ease and convenience of use, prolonged retention and
reduced leakage due to the bioadhesive nature of the carrier polymer
and prolonged release due to gel formation of the polymer which pro-
vides a diﬀusion barrier to release. Such a system would potentially
allow release over a period of hours which may potentially optimise the
treatment regimen and allow daily use for women deemed to be at high
risk of early labour.
Nanoﬁbrous approaches are attracting increasing interest within the
pharmaceutical arena, particularly as the issue of poor yield is now
becoming more eﬀectively addressed, thereby rendering large scale
production feasible. Pressurised gyration (PG) is a recently developed
processing method which involves simultaneous centrifugal spinning
and solution blowing to produce polymeric nano- and microﬁbers
(Mahalingam and Edirisinghe, 2013). The laboratory-scale PG equip-
ment consists of a cylindrical aluminium vessel of approximately
60mm in cross-sectional diameter and 35mm in height, capable of
rotational speed of up to 36,000 rpm. The ﬁbers are rapidly extruded as
a polymeric solution under conditions of high rotation and enhanced
pressure via a gas input through a series of holes with diameter of
0.5 mm, resulting in rapid evaporation of the solvent and collection of
the resulting nano- or microﬁbers on a surround plate (for more details
see Mahalingam and Edirisinghe, 2013). PG has successfully been used
to manufacture nanoﬁbers for a variety of pharmaceutical applications
including the generation of amorphous drug dispersions (Raimi-
Abraham et al., 2014) and microbubbles (Mahalingam et al., 2014).
PG represents a promising development for large scale production;
while electrospinning remains the most widespread method of produ-
cing ﬁbers (Eatemadi et al., 2016), the limitations of scale-up have
restricted the use of this approach within the pharmaceutical arena. PG
has advantages of simplicity, low cost, high yield and versatility, having
already been used for the production of a range of materials from
ceramics (Mahalingam et al., 2015) to shape memory 3D mats (Wu
et al., 2017). Here we further develop the technique for pharmaceutical
applications, with a particularly view to addressing the persistent
question of how hydrophobic drugs may be incorporated into hydro-
philic polymers. In our previous work, we demonstrated the possibility
of generating nanoﬁbers with suitable mucoadhesive properties from a
range of polymers using PG (Brako et al., 2015). These included
bioadhesive polysaccharides (sodium alginate) and synthetic or semi-
synthetic polymers (polyacrylic acid and carboxymethyl cellulose
(CMC)), using a spinning agent polyethylene oxide (PEO) to elicit suf-
ﬁcient chain entanglement in the liquid state so as to ultimately allow
for ﬁber formation. The study discussed here takes the work described
above into the arena of drug-loaded systems in that it explores the
possibility of incorporating progesterone into nanoﬁbers as a potential
precursor for a bioadhesive vaginal drug delivery system. More speci-
ﬁcally, the aim of the study was to explore the manufacturing condi-
tions (solvent choice, material composition and drug loading) for the
production of drug-loaded PEO ﬁbers so as to develop an optimised
prototype for bioadhesive delivery, with associated inherent ad-
vantages of high surface area for both adhesion and release. PEO and
CMC blend yielded ﬁbers with optimal prospects for mucoadhesion and
was therefore chosen for drug loading and compared with PEO in this
study. Given the hydrophobicity of progesterone, a particular challenge
and objective was to examine the incorporation of the drug into the
water-miscible polymeric carrier systems. However, if it were possible
to successfully incorporate the drug into such polymers the possibility
of then using the product as the basis for a delivery system then be-
comes feasible. Our aim was therefore to examine the manufacture,
drug incorporation, characterization and release characteristics of
progesterone-loaded nanoﬁbers using a blend of bioadhesive polymers.
2. Materials and methods
2.1. Materials
Sodium carboxymethylcellulose (CMC) (Mw∼ 250,000 gmol−1),
poly (ethylene oxide) (PEO) (Mw∼ 200,000 gmol-1), progesterone
(Mw∼ 314 gmol−1, aqueous solubility: 8.81mg/L (at 25 °C), log P:
3.87) and ethanol were obtained from Sigma-Aldrich UK. All were used
without further puriﬁcation. Puriﬁed distilled water and ethanol mix-
tures (as speciﬁed) were used as solvents throughout the study.
Simulated vaginal ﬂuid (pH=4.7), prepared according to a formula
developed by Owen and Katz (1999); contained sodium chloride
(3.51 g/L), potassium hydroxide (1.40 g/L), calcium hydroxide
(0.222 g/L) and bovine serum albumin (BSA) (0.018 g/L). Other com-
ponents were acetic acid (1.00 g/L), lactic acid (2.00 g/L), glucose
(5.0 g/L), urea (0.4 g/L), glycerol (0.16 g/L) and porcine mucin type II
(1.5% w/v). All of these were also obtained from Sigma-Aldrich. Cel-
lulose acetate membranes of pore size 0.2 µm were used for permeation
studies; these were obtained from Sartorius, Gottingen, Germany. Pro-
gesterone released from ﬁbers were compared to Cyclogest® 200mg, a
vaginal pessary formulation (weighing 1.825 g) obtained from Actavis,
Barnstaple, UK.
2.2. Methods
2.2.1. Preparation and characterisation of polymer solutions
Uniform mixtures of PEO, blends with CMC and progesterone were
obtained by continuous magnetic stirring followed by sonication for
10min using a Branson Soniﬁer 250 (Danbury, Connecticut, USA).
Speciﬁcally, water and ethanol (equal part mixture) was added to
premixed powders of progesterone and polymers in quantities shown in
Table 2. The viscosities of the resulting polymer-drug solutions were
measured using Brookﬁeld DV-111 rotational viscometer (Harlow, UK)
with spindle size 18 at a shear stress of 3.5 Pa. Surface tension was
measured using Kruss K9 tensiometer (Hamburg, Germany). All ex-
periments were conducted at 25 °C and ﬁve separate measurements
were taken and their means calculated. Equipment were calibrated
prior to measurements. The viscometer was calibrated automatically by
running a complete cycle without the spindle in place while the tensi-
ometer was calibrated by taking the surface tension of distilled water at
room temperature, comparing with literature values and adjusting ac-
cordingly.
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2.2.2. Fiber preparation and characterisation
Fibers were produced by pressurised gyration at ambient tempera-
ture (25 °C) using a method described previously (Mahalingam and
Edirisinghe, 2013). Brieﬂy, 3ml of drug-polymer mixture prepared
using 1:1 mixture of water and ethanol (selected based on data shown
in Table 1) was placed in the aluminium vessel and spun at a rotational
speed of 24,000 rpm and a working pressure of 0.15MPa to produce
progesterone-loaded ﬁbers. The morphology and size of ﬁbers were
studied using scanning electron microscopy, while their material com-
positions were analysed using thermal and spectroscopic techniques.
Details of various techniques used in further characterisation studies
are described below.
2.2.3. Drug loading
The progesterone content within the ﬁbers generated was de-
termined following the standard assay procedure of dissolution in
ethanol for detection by UV at 241 nm (NCBI, 2004). UV analysis was
chosen as PEO has no active UV chromophores and hence minimal
interference with assay of progesterone was anticipated. 1mg of ﬁbers
were dissolved in 10ml of absolute ethanol in a volumetric ﬂask. The
ﬂask was swirled gently over a period of 24 h to ensure complete re-
moval of progesterone from ﬁbers into the ethanol. 3 ml of resultant
solution was drawn and analysed spectrophotometrically at 241 nm
using a Jenway 6305 UV/Visible spectrophotometer (Bibby Scientiﬁc,
Staﬀordshire, UK). The% loading was calculated by expressing the drug
content in a given weight of ﬁber as a percentage.
2.2.4. Hot stage microscopy
Hot-Stage Microscopy (HSM) studies were conducted on a Leica DM
2700M microscope (Leica Microsystems, Wetzlar, Germany) ﬁtted with
Inﬁnity 2 digital camera (Lumenera Corporation, Ottawa, Canada). The
unit was used to visually observe the melting of ﬁbers on a FP5/FP52
heating stage unit controlled by FP90 central processor unit, both from
Mettler-Toledo Ltd, Leicester, UK. Fibers containing progesterone were
heated from 50 to 130 °C at a rate of 2 °C/min while unloaded PEO
ﬁbers were heated from 50 to 70 °C at the same rate.
2.2.5. Attenuated total reﬂection Fourier transform infrared spectroscopy
(ATR-FTIR)
The chemical composition of the ﬁbers was investigated using
Attenuated Total Reﬂection Fourier Transform Infrared spectroscopy
(ATR–FTIR) measurements (Bruker Vertex 90 spectrometer), and
spectrographs were interpreted using OPUS Viewer version 6.5 soft-
ware. Each sample had 32 scans at a resolution of 4 cm−1. The same
parameters were used for background scans before each sample was
analysed. The CMC spectra partially overlapped with the PEO and
progesterone and is present as a minority component in the ﬁbers,
thereby considerably complicating analysis; consequently, the results
presented here are for PEO and the active only.
2.2.6. X-ray powder diﬀraction
Structure and crystalline forms of the content of ﬁbers were studied
using D/Max-BR diﬀractometer (RigaKu, Tokyo, Japan) with Cu Kα
radiation. Analyses were conducted at 40mV and 30mA over 2θ range
of 5–60° at a rate of 2°/min. Data obtained were converted to dif-
fractograms and evaluated using OriginPro 7.0 software (OriginLab
Corporation, MA, USA).
2.2.7. Release studies
In vitro drug release studies were carried out using Franz diﬀusion
cells with cellulose acetate membranes of pore size 0.2 µm previously
immersed in simulated vaginal ﬂuid (SVF) for 30min. The basis for
selecting this approach to the study of release is the high correlation
that exists between drug permeation through a 0.2 µm acetate mem-
brane and the mucosal membrane, demonstrated in a study in-
vestigating the use of artiﬁcial membranes as a rapid screening alter-
native to natural mucosa (Khdair et al., 2013). The membrane was
mounted onto the diﬀusion cell with the help of a pair of tweezers after
3ml of phosphate-buﬀered saline (PBS, pH 7.4) and a magnetic stirrer
was placed in the receptor chamber to ensure adequate mixing of
progesterone transported through the membrane into the buﬀer solu-
tion in the accepting chamber. Systems containing 25mg of proges-
terone in 1ml of SVF were placed in the donor chamber. The apparatus
was kept at a constant temperature of 37 °C. The amount of drug re-
leased through the membrane at various predetermined time points
were determined after drawing 1ml aliquots from the receptor chamber
and quantiﬁed using UV spectroscopy. Sample volumes were replaced
with fresh PBS solution. The possibility of membrane deterioration and
pore plugging after an extended period of use (Gekas and Hallström,
1990) was anticipated and hence measurements were performed over a
period under 4 h to minimise the chances of this eventuality occurring.
Results were compared to those obtained by replacing ﬁbers with a
sample of the progesterone pessary (Cyclogest) containing an equiva-
lent amount of drug (25mg); the temperature of the analysis allowed
spreading of the material on the membrane.
3. Results and discussion
3.1. Processing and characterisation of progesterone-loaded nanoﬁbers
Fiber formation by the PG process is generally inﬂuenced by a
number of factors including solution properties (e.g. viscosity and
surface), processing parameters (i.e. working pressure and rotational
speed) and environmental parameters (i.e. temperature and humidity)
Table 2
Viscosity and surface tension of drug-polymer mixtures used in generating ﬁbers.
Fiber composition (wt.%) Viscosity (mPa s)± SD Surface tension (mNm − 1)± SD
Polymer Drug
PEO CMC Progesterone
15 0 1 4065 ± 3 47.8 ± 0.2
13.75 1.25 1 5284 ± 9 53.5 ± 0.5
15 0 5 7593 ± 13 54.0 ± 0.2
13.75 1.25 5 8220 ± 30 55.7 ± 0.4
Table 1
Percentage drug loading in ﬁbers produced using water and ethanol mixtures in diﬀerent
ratios, 15% w/w PEO and 1% w/w progesterone. Drug content refers to loading in ﬁbers
following production.
Sample Solvent system (% w/w)Ethanol Water Drug content (% w/w)
1 10 90 0.5
2 20 80 2.0
3 30 70 3.0
4 40 60 4.5
5 50 50 7.7
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(Mahalingam and Edirisinghe, 2013). In this study, production condi-
tions such as solvent choice, polymeric materials used (single or blend
of polymers) and drug loading were investigated to determine their
inﬂuence on ﬁber outcome and drug encapsulation.
3.1.1. Choice of solvent system
As PG is a solvent-based method for manufacturing nanoﬁbers,
solvent choice is a key parameter for consideration. Progesterone is
soluble in ethanol (up to 100mg/ml) and virtually insoluble in water
(< 1mg/ml at 19 °C) while PEO and CMC are poorly soluble in ethanol
but soluble in water. Solvent systems with varying proportions of
ethanol and water were therefore investigated to select the type with
highest possible drug loading while also producing satisfactory ﬁbers.
Speciﬁcally, solvent systems of ethanol and water containing 10, 20, 30,
40, and 50% of ethanol were used to prepare solutions containing a
standard PEO and drug composition (15% w/w PEO and 1% w/w
progesterone) from which nanoﬁbers were generated. Drug loading in
the dry ﬁbers (as opposed to the initial solutions) was assessed for each
composition and is shown in Table 1, noting that the theoretical max-
imum is 6.25% w/w.
As seen in Table 1, the amount of drug encapsulated in the ﬁbers
increased with ethanol content, reﬂecting the higher solubility of drug
in such solvents; notably, the solvent system containing 50% ethanol
resulted in ﬁbers with considerably higher drug loading (the excess
over maximum probably reﬂecting some polymer not forming ﬁbers).
Systems with more than 50% ethanol resulted in mixtures with un-
dissolved polymer and were hence unsuitable for ﬁber formation. On
the basis of these observations, a 1:1 mixture of water and ethanol was
chosen for further investigations.
3.1.2. Solution properties
Various drug-polymer solutions (using 1:1 ethanol water as solvent)
using either PEO only or PEO/CMC blends, with 1 or 5 wt% proges-
terone, were prepared and characterised prior to spinning in order to
examine the inﬂuence of solution properties (viscosity and surface
tension) as well as initial drug loading on the drug-loaded ﬁber for-
mation. While a direct correlation between viscosity and ﬁber outcome
has been established (high viscosity typically yielding ﬁbers of greater
diameter), surface tension typically determines the upper and lower
boundaries of solution spinnability. Outside this range, ﬁbers may be
heavily beaded at high surface tension or may not form at all at the
lower values (Mahalingam and Edirisinghe, 2013; Padron et al., 2013).
In this work, all solutions were within a suitable surface tension range.
A summary of the drug-polymer solutions from which ﬁbers were
generated and their properties is given in Table 2.
Both drug and polymer constituents inﬂuenced the solution prop-
erties, with changes in viscosity considerably more marked than those
in surface tension. The inclusion of CMC, primarily to improve the
bioadhesive properties of ﬁbers (Brako et al., 2015), increased the
viscosity of the systems; CMC is well known as a viscosity modiﬁer, the
extent being dependent on the degree of methyl substitution (DS) on
the cellulosic backbone (Barba et al., 2002). More surprisingly, the
increase from 1 to 5 wt% progesterone loading also had a signiﬁcant
eﬀect on viscosity, with an increase > 40% noted for this parameter.
Fiber images and size (diameter) distribution generated from drug-
polymer solutions with 5 wt% progesterone initial loading are shown in
Fig. 1.
In our previous study (Brako et al., 2015), whereby ﬁbers were
produced from similar polymer composition without progesterone, the
average diameters for PEO and PEO/CMC blends were 172 and 194 nm
respectively. Here, the same polymer constituents yielded ﬁbers aver-
aging 394 and 404 nm respectively, demonstrating the inﬂuence of
progesterone inclusion on ﬁber production by PG. This observation is
also in keeping with the increase in viscosity caused by the inclusion of
the drug as noted in Table 2.
3.1.3. Drug entrapment in PEO and PEO/CMC systems
The eﬀects of initial drug concentration on entrapment eﬃciency in
progesterone-loaded ﬁbers was examined. The solvent system chosen
for this study allowed initial drug loading up to 5 wt%, beyond which
the system did not produce satisfactory ﬁbers. Progesterone content in
ﬁbers produced from either 1% or 5% wt. initial drug loading was
determined by UV/Vis spectroscopy as described in Section 2.2.3. The
results are shown in Fig. 2; in all cases the loading was close to the
theoretical values of 6.25% and 25% w/w for the 1% and 5% w/w
loading respectively. A further observation was that polymer compo-
sition did not appear to aﬀect drug loading.
3.2. ATR-FTIR analysis
To further characterise the ﬁbers and conﬁrm drug entrapment,
ATR-FTIR analyses were conducted on systems with an initial (solvent)
loading of 5% progesterone and 15% PEO in order to conﬁrm the
composition of the product via characteristic functional groups. In ad-
dition, the approach is useful for identifying the possibility of drug-
polymer interactions.
The ATR-FTIR spectra of PEO and progesterone is shown in Fig. 3.
For the progesterone, peaks indicating carbonyl stretching bands at C3
and C20 (characteristic of two ketone groups at C3 and C20 which ty-
pically distinguishes progesterone from other steroids) within the mo-
lecule can be seen at 1661 and 1693 cm−1 respectively (Benoit et al.,
1986) The characteristic peak at 843 cm−1 resulting from –CH2–CO
rocking/stretching in PEO is also shown (Frech and Huang, 1995; Li
and Hsu, 1984). All characteristic peaks for both compounds can be
seen in ATR-FTIR spectra of progesterone loaded PEO ﬁbers (Fig. 3).
Identifying characteristic bands conﬁrms the residual material seen
beyond the melting point of PEO from the HSM as progesterone. No
evidence was seen of polymer-drug interactions via shifts in char-
acteristic peaks, nor was evidence found for amorphous drug via
broadening of peaks.
3.3. Microscopic assessment of drug incorporation
When observed using optical microscopy, the ﬁbers could be vi-
sualised as bundles rather than individual ﬁbers. The crystalline prop-
erties of the drug within the polymeric carrier was investigated by
examination of such ﬁber bundles using hot stage microscopy. PEO is a
semi-crystalline polymer which has a melting temperature of ∼60 °C
whilst progesterone has a melting temperature of ∼120 °C. The dif-
ference in melting points makes possible the visualisation of how var-
ious components of drug-loaded ﬁbers will react to temperature ele-
vation in terms of diﬀerential temperatures of melting, thereby
potentially allowing visualisation of the drug crystals released from the
ﬁbers above the melting point of the latter.
Hot stage microscopy (HSM) studies were conducted on PEO and
PEO-progesterone ﬁbers to visualise any changes that occurred on
heating. PEO (Fig. 4a, stages 1–4) and progesterone loaded PEO
(Fig. 4b, stages 1–4) ﬁbers were heated from 50 to 95 °C. HSM studies
conﬁrmed that PEO ﬁbers melted at∼ 65 °C and completely without a
trace of any other component at 95 °C (stage 4). In contrast, Fig. 4b
stage 4 (i.e. 95 °C), shows the presence of particles (or more speciﬁcally
particle aggregates, as conﬁrmed by SEM (data not shown)) which we
ascribe to progesterone crystals as they are visible above the melting
point of PEO. This in turn indicates that the progesterone is in-
corporated as crystals rather than as a molecular dispersion within the
ﬁbers. Further analysis by X-ray diﬀraction (Section 3.4 below) was
performed to conﬁrm the crystalline structure and composition of the
ﬁbers.
3.4. X-ray diﬀraction (XRD) studies
XRD studies were conducted on the unloaded 15% PEO and 5% w/v
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progesterone loaded systems (% w/w referring to initial solvent
loading) to conﬁrm the solid state of encapsulated progesterone in the
PEO ﬁbers.
Several diﬀraction peaks are seen in both the PEO and progesterone
XRPD patterns (Fig. 5). Peaks A and B at 22.4 and 18.7 2Θ degrees
indicates crystallinity for PEO while peaks C and D at 12.7 and 16.9
conﬁrms crystallinity in the progesterone powders used in this study
(Oliveira et al., 2013; Sangawar and Bhagat, 2013).
The progesterone loaded PEO ﬁber (Fig. 5) shows all the char-
acteristic peaks (A, B, C, and D) seen in each of the pure samples in-
dicating that the progesterone was indeed encapsulated in the PEO in
crystalline form. The halo diﬀraction pattern seen between 10 and 40
Fig. 1. SEM images and size distribution curve for a) PEO
progesterone-loaded ﬁbers (produced from solution con-
taining 5% wt. progesterone and 15% wt. PEO), average
size 349 nm with 22% dispersity and b) PEO/CMC proges-
terone-loaded (produced from solution containing 5% wt.
progesterone, 13.75% wt. PEO and 1.25% wt. CMC),























Progesterone in drug-polymer solution  
PEO Only
PEO/CMC
Fig. 2. Comparison of progesterone content in ﬁbers produced from 15% wt. PEO (PEO
only) or 13.75% wt. PEO and 1.25% wt. CMC (PEO/CMC) and with an initial drug
loading of either 1% or 5% wt. progesterone.
Fig. 3. TR-FTIR spectra of PEO and progesterone in the 600–2600 cm−1 region showing
characteristic peaks and that of drug-loaded PEO (with initial solvent loading of 5%
progesterone) ﬁbers conﬁrming the presence of encapsulated progesterone.
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Fig. 4a. Melting of PEO ﬁber bundle without progesterone (stages 1–4 representing temperatures 50 °C, 61 °C, 64 °C and 95 °C) visualised by hot-stage microscopy. At stage 4, the PEO
ﬁber had melted completely.
Fig. 4b. Melting of PEO ﬁber (with initial solvent loading of 5% Progesterone) (stages 1–4 representing temperatures 50 °C, 61 °C, 64 °C and 95 °C) visualised by hot-stage microscopy.
F. Brako et al. International Journal of Pharmaceutics 540 (2018) 31–39
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2Θ in the drug loaded ﬁbers is characteristic of amorphous material
(Jain et al., 2008; Young, 2012) conﬁrming a degree of amorphous
characteristics in the drug-loaded ﬁber, most likely associated with the
polymeric carrier.
3.5 In-vitro drug release studies
In vitro drug release studies were conducted on progesterone loaded
PEO and PEO/CMC ﬁbers (solvent loading 5% w/v active) and com-
pared (under the same experimental conditions) with that of Cyclogest,
a commercial pessary containing progesterone. The experimental ap-
proach was designed to observe progesterone release from nanoﬁbers
across an artiﬁcial membrane mimicking the mucosal environment of
the vagina, particularly to ascertain whether the ﬁbers showed release
over a period of time commensurate with that required clinically
(which would be a period of hours for daily administration).
As seen in the release proﬁles (Fig. 6), the release of the drug from
the ﬁbers and the commercial pessary were comparable although the
release from the ﬁbers was somewhat more rapid. Given the high sur-
face area and hydrophilicity of the polymer this is to be expected, al-
though the presence of the crystalline form of the drug and the pro-
pensity for gel formation in the microenvironment surrounding the
hydrated nanoﬁbers augers well for a release rate that is suﬃciently
slow as to provide day-long protection for the patient. The correlation
coeﬃcients from release proﬁles of nanoﬁber systems and Cyclogest
when ﬁtted in a zero-order model were 0.955, 0.979 and 0.893 for PEO,
PEO/CMC and Cyclogest formulations respectively, indicating that over
the time period under study the release proﬁles are eﬀectively linear.
Furthermore, it was observed that the inclusion of CMC had a limited
eﬀect on drug release in that some slowing of release was observed
compared to the PEO alone.
3.6. Overarching comments
Taken together, the data show that the ﬁbers may both incorporate
progesterone and release the drug at a rate commensurate with a
commercial product. Furthermore, the ability to now manufacture na-
noﬁbers at scale presents this approach to delivery as a viable addition
to the current available approaches. While ﬁber-based vaginal delivery
systems are being explored for interventions in other therapeutic areas
such as infection management (Sharma et al., 2016) and the prevention
of HIV transmission (Ball and Woodrow, 2014; Blakney et al., 2013;
Krogstad and Woodrow, 2014), previous work on developing proges-
terone delivery systems for vaginal application have not thus far uti-
lised drug-loaded ﬁbers. Indeed, the development of new delivery sys-
tems for progesterone has been more focused on hormone replacement
therapy and contraception (Friend, 2016). Considering the promise of
ﬁber-based vaginal delivery systems in other therapeutic areas, there is
a compelling argument for utilising the formulation approach for this
particular drug and application. Indeed, our approach does present
some tangible potential advantages, notably in the ability to combine
mucoadhesion with a ﬂexible delivery system which can reshape itself
Fig. 5. X-ray diﬀractograms comparing the characteristic reﬂection peaks of their crys-
talline nature of PEO and progesterone powders to those in progesterone-loaded PEO






















Fig. 6. Release proﬁles of progesterone loaded PEO and PEO/CMC ﬁbers and Cyclogest in stimulated vaginal ﬂuid.
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to ﬁt on to the vaginal wall while also allowing control of release via gel
formation. In this particular study we have focused on the incorpora-
tion of the poorly water-soluble drug progesterone rather than the
bioadhesion and swelling aspects; our previous work (Brako et al.,
2015) has studied the adhesive properties of the ﬁbers and we will
shortly be reporting on a novel AFM-based technique to examine both
swelling and adhesion. Here, we have demonstrated the incorporation
of a relevant yet poorly water-soluble drug into hydrophilic nanoﬁbers,
the possibility of manufacture using the novel technique of pressurised
gyration which indicates commercial production is feasible and ﬁnally
the establishment of a release proﬁle which is in line with a commercial
formulation. Taken together, the study has shown that the nanoﬁber
approach to vaginal delivery is a feasible methodology from a manu-
facturing viewpoint. Issues such as irritation and cytotoxicity would
obviously need to be considered, although materials used for the
manufacture of the ﬁbers are widely used as food and pharmaceutical
excipients as they are conﬁrmed to be non-toxic and non-irritant (Rowe
et al., 2006). Indeed, PEO and CMC are currently in use as excipients for
vaginal formulations or on their own, for instance in managing vaginal
dryness (das Neves and Bahia, 2006). We therefore suggest that ﬁber
–based approaches to vaginal delivery have considerable potential,
both therapeutically and commercially and, while the focus in the
present case is pre-term birth, the possibilities for a range of conditions
such as infection and inﬂammation is clear.
4. Conclusion
The poorly water-soluble drug progesterone has been successfully
loaded in nanoﬁbers generated by pressurised gyration. A solvent
system composed of ethanol and water in equal parts enabled the for-
mation of a drug-polymer solutions from which ﬁbers were formed.
Fibers produced had diameters from 40 to 1000 nm with average dia-
meter dependent on amounts of polymer and progesterone therein. By
varying production condition such as solvent system and initial drug
loading, up to 25% wt. drug loading was achieved. Drug entrapment
eﬃciency across batches with diﬀerent polymer compositions were si-
milar, though decreased in batches with higher amount of initial drug
loading. Thermal and spectroscopic analyses conﬁrmed that some of the
entrapped remained in the crystalline state. The drug-loaded ﬁbers
showed more uniform release of higher amount of progesterone when
compared to release Cyclogest, but nevertheless indicated release over a
period of several hours. These drug-loaded ﬁbers have demonstrated
potential for eﬃcient drug loading and prospects of optimal release
kinetics. In addition, their surface properties and mucoadhesive pro-
spects could be explored further for both prolonged localisation against
the mucosal membrane and, potentially, enhanced trans-mucosal de-
livery aided by adhesion. The progesterone-loaded ﬁbers produced and
analysed have therefore proved to be promising materials for the de-
livery of progesterone to the vaginal mucosal membrane.
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